Edition:
United Kingdom

Xvivo Perfusion AB (XVIVO.ST)

XVIVO.ST on Stockholm Stock Exchange

116.00SEK
10:21am BST
Change (% chg)

-1.00kr (-0.85%)
Prev Close
117.00kr
Open
117.80kr
Day's High
117.80kr
Day's Low
115.60kr
Volume
2,174
Avg. Vol
39,792
52-wk High
123.40kr
52-wk Low
82.00kr

Latest Key Developments (Source: Significant Developments)

Xvivo Q3 EBITDA ex-items at SEK 4.4 million
Friday, 27 Oct 2017 

Oct 27 (Reuters) - XVIVO PERFUSION AB ::Q3 NET SALES SEK ‍32.3​ MILLION VERSUS SEK 31.7 MILLION YEAR AGO.Q3 EBITDA EX-ITEMS SEK ‍4.4​ MILLION VERSUS SEK 5.4 MILLION YEAR AGO.  Full Article

XVIVO Perfusion plans private placement
Friday, 17 Mar 2017 

Xvivio Pwerfusion AB : Announced on Thursday its intention to undertake a private placement of shares . Said intends to offer up to 2,361,408 new shares . The subscription price for the shares in the private placement will be determined in the book building process .Said reason behing private placement is to broaden the shareholder base, said directed share issue means lower costs and faster process.  Full Article

Xvivo Perfusion Q2 EBITDA ex-items up at SEK 6.9 million
Friday, 15 Jul 2016 

Xvivo Perfusion AB : Q2 net sales 34.5 million Swedish crowns ($4.1 million) versus 29.1 million crowns year ago . Q2 EBITDA ex-items 6.9 million crowns versus 4.6 million crowns year ago . Says focus during 2016 is therefore to establish STEEN Solution method as the standard treatment for lung transplantation .Since acquisition of Vivoline company will intensify research and development in cardiac transplantation.  Full Article

Xvivo Perfusion: share warrant program fully subscribed
Friday, 8 Jul 2016 

Xvivo Perfusion AB :Upon full exercise of warrants, share capital increase is around 5,500 Swedish crowns ($650) corresponding to a dilution of about 0.9 percent of total number of shares and votes.  Full Article

BRIEF-Xvivo Perfusion Q1 Adjusted. EBITDA Sek 7.2 Million

* Q1 ADJUSTED. EBITDA SEK 7.2 MILLION VERSUS SEK 5.0 MILLION YEAR AGO